Introduction：Basic information about CAS 203787-91-1|Salcaprozate sodium, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Salcaprozate sodium |
|---|
| CAS Number | 203787-91-1 | Molecular Weight | 301.313 |
|---|
| Density | / | Boiling Point | 521.7ºC at 760 mmHg |
|---|
| Molecular Formula | C15H20NNaO4 | Melting Point | / |
|---|
| MSDS | / | Flash Point | 269.3ºC |
|---|
Names
| Name | Salcaprozate sodium |
|---|
| Synonym | More Synonyms |
|---|
Salcaprozate sodium BiologicalActivity
| Description | Salcaprozate sodium (SNAC), an oral absorption promoter, and has the potential as a delivery agent for oral forms of heparin and insulin. Salcaprozate sodium could increase passive transcellular permeation across small intestinal epithelia based on increased lipophilicity arising from non-covalent macromolecule complexation[1][2]. |
|---|
| Related Catalog | Research Areas >>OthersSignaling Pathways >>Others >>Others |
|---|
| In Vitro | SNAC (12.5-400 μg/mL; 24 h) has no toxicity to Caco-2 cells, and the survival percentage is above 90% when SNAC is 200 μg/mL[3]. SNAC (50 and 200 μg/mL) improves the apparent permeability coeffcient (Papp) of RA and SA-B by 2.14-fold and 3.68-fold compared with the Papp of SAs solution[3]. |
|---|
| In Vivo | SNAC improves the oral absorption of both R1 and SAs and enhances bioavailability in rats[3]. SNAC (2000 mg/kg/d; oral gavage for 13 weeks) related mortality is evident only at the 2000-mg/kg/d level, 20% among males and 50% among females; no clear cause of death is evident[1]. SNAC (100-1000 mg/kg/d; oral gavage for 13 weeks) induces no mortality in the Wistar rat study at doses up to 1000 mg/kg/d[1]. Animal Model: Sprague-Dawley rats (6-7 weeks)[1] Dosage: 2000 mg/kg/d Administration: Oral gavage for 13 weeks Result: Induced 20% and 50% mortality in males and females at the dose of 2000 mg/kg/d. |
|---|
| References | [1]. Riley MGI, et, al. Subchronic oral toxicity of salcaprozate sodium (SNAC) in Sprague-Dawley and Wistar rats. Int J Toxicol. Jul-Aug 2009; 28(4):278-93. [2]. Twarog C, et, al. Intestinal Permeation Enhancers for Oral Delivery of Macromolecules: A Comparison between Salcaprozate Sodium (SNAC) and Sodium Caprate (C 10). Pharmaceutics. 2019 Feb 13; 11(2):78. [3]. Li Y, et, al. Impact of Sodium N-[8-(2-Hydroxybenzoyl)amino]-caprylate on Intestinal Permeability for Notoginsenoside R1 and Salvianolic Acids in Caco-2 Cells Transport and Rat Pharmacokinetics. Molecules. 2018 Nov 16; 23(11):2990. |
|---|
Chemical & Physical Properties
| Boiling Point | 521.7ºC at 760 mmHg |
|---|
| Molecular Formula | C15H20NNaO4 |
|---|
| Molecular Weight | 301.313 |
|---|
| Flash Point | 269.3ºC |
|---|
| Exact Mass | 301.128998 |
|---|
| PSA | 89.46000 |
|---|
| LogP | 1.60340 |
|---|
| Vapour Pressure | 1.03E-11mmHg at 25°C |
|---|
Synonyms
| Sodium 8-[(2-hydroxybenzoyl)amino]octanoate |
| E414 |
| Octanoic acid, 8-[(2-hydroxybenzoyl)amino]-, sodium salt (1:1) |
| Salcaprozate sodium |
| SNAC |
